Emery Pharma has expanded its state-of-the-art laboratories which feature a brand-new High-Resolution Orbitrap Mass Spectrometer, enabling the company to increase its service offerings.
 
The extension of its new laboratory is streamlined to support the research and development of large molecule drugs, including biologics, antibody-drug conjugates, biosimilars and more.
 
In addition to the High-Resolution Orbitrap Mass Spectrometer, the newly established laboratory features brand-new instruments for Ultrahigh Performance Liquid Chromatography (UPLC) equipped with a Diode Array Detector (DAD), Charged Aerosol Detector (CAD), and Refractive Index (RI) detector, Gas Chromatography Mass Spectrometry (GC-MS), and Semi-Preparative High-Performance Liquid Chromatography (HPLC). With the addition of these new top-of-the-line instruments, Emery Pharma continues to offer quality, flexibility, and innovative concepts to help accelerate the drug development process.
 
Emery Pharma’s expertise also continues to grow with the addition of Dr. Rodney Bannwart, who has considerable experience in pharmaceutical analysis, holding advanced scientific positions at Pfizer, Abbott, Novartis, and Alcon.
 
“Rodney is a pharmaceutical veteran and previously jumpstarted Alcon’s Biologics Mass Spectrometry capabilities with great success. We are excited for him to lead the new Large Molecule Analytical Division at Emery Pharma,” said Dr. Neel Bose, CSO.